CytoMed TherapeuticsGDTC
Market Cap: 20.9M
About: CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Employees: 34
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
0.04% less ownership
Funds ownership: 0.04% [Q4 2023] → 0% (-0.04%) [Q1 2024]
50% less funds holding
Funds holding: 2 [Q4 2023] → 1 (-1) [Q1 2024]
100% less capital invested
Capital invested by funds: $21.5K [Q4 2023] → $28 (-$21.4K) [Q1 2024]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price forecasts over the past 6 months
1 analyst rating
Benchmark Bruce Jackson | 176%upside $5 | Speculative Buy Reiterated | 11 Jun 2024 |